Research
GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma
PLOS ·
The Brief
- BRAFV600E mutations drive constitutive MAPK signaling across various cancers.
- Resistance to MEK inhibitors such as trametinib undermines their clinical benefit.
- The study reports that GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma.
Why it matters
The study identifies a signaling pathway that can sustain MAPK activity despite MEK inhibition, which may point to ways of overcoming treatment resistance in BRAF-mutant melanoma.
Who’s affected
- cancer researchers studying melanoma and MAPK pathway inhibitors
- #melanoma
- #braf
- #mek inhibition
- #gpcr
- #drug resistance
by Jingyi Ke, Zi Wang, Zhengyang Guo, Guangshuo Ou, Wei Li Oncogenic BRAFV600E mutations drive constitutive MAPK signaling across various cancers; however, resistance to MEK inhibitors such as trametinib undermines clinical benefits, and the mechanisms sustaining MAPK activity…